Loading…
← CockpitCompetitor Analysis › KURN.SW Kuros Biosciences Ltd.Open in the cockpit ↗

Kuros Biosciences Ltd.KURN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties
Momentum laggard 12
Mkt cap
$907M
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$4.14M
20-day average traded
Fwd P/E
70.5×
forward earnings
ROIC−WACC
+3.9 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · CHFCHF 19.20
1D-0.7%
1W-4.5%
1M+2.5%
3M-10.8%
6M-12.5%
YTD-30.1%
1Y-29.8%
ATR %4.9%
52w lowhigh40.9% off high

What Kuros Biosciences does

Employees: 178

Kuros Biosciences at a glance

Size Kuros Biosciences (KURN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $907M, the 122nd largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 19.20 on 18 Nov 2026.

Performance Over six months the shares fell 12.5%, against -13.2% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 40.9% over the last twelve months (peer median +6.0%); the operating margin is 6.0% (peer median 9.6%).

Valuation It trades at 70.5× forward earnings against a peer median of 21.7× (3rd most expensive of 17).

Capital Return on invested capital runs 3.9 points above its cost of capital (5.0% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026KURN.SW 89Peer median 87
Six months, rebased to 100: Kuros Biosciences against the median of its 20 peers (local-currency closes).

Kuros Biosciences financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 139MCHF 121MCHF 75.0MCHF 33.6MCHF 18.0M
Revenue growth—+62%+123%+87%—
Gross profitCHF 118MCHF 105MCHF 65.9MCHF 27.8MCHF 13.8M
EBITDACHF 11.6MCHF 10.1MCHF 2.61M-CHF 2.58M-CHF 7.37M
Net incomeCHF 7.12MCHF 2.12M-CHF 4.26M-CHF 13.7M-CHF 14.6M
Free cash flow-CHF 6.61M-CHF 2.40MCHF 2.03M-CHF 9.16M-CHF 7.74M
Capital expenditureCHF 6.32MCHF 2.03MCHF 1.10MCHF 326,000CHF 400,000
Total debtn/aCHF 3.94MCHF 4.92MCHF 5.52MCHF 7.72M

Quarterly statements and history in the cockpit →

Kuros Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%AORTBVS3015806885756887676886262906506882777780002658SFL688656301602304677303600300143KIDSKURN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Kuros Biosciences is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×AORTBVS3015806885756887676886267780002658SFL688656304677306033671187300143KURN.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kuros Biosciences is the large dot.

Kuros Biosciences competitors and peer comparison

How Kuros Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kuros Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureKURN.SWPeer medianRank in peer set
1-month return+2.5%-8.0%6th highest of 21
6-month return-12.5%-13.2%11th highest of 21
Distance from 52-week high-40.9%-38.6%10th lowest of 21
Revenue growth (TTM)+40.9%+6.0%2nd highest of 21
Operating margin6.0%9.6%6th lowest of 21
Forward P/E70.5×21.7×3rd most expensive of 17
ROIC minus cost of capital+3.9 pp+2.4 pp9th highest of 21
EV / EBITDA66.5×9.9×most expensive of 9
Net debt / EBITDA0.3×0.3×5th least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a

Questions

Which companies are Kuros Biosciences's closest peers?
The cockpit's peer set: Artivion (AORT), Bioventus (BVS), Aidite (Qinhuangdao) Technology (301580.SZ), Shenzhen YHLO Biotech (688575.SS), Hangzhou Biotest Biotech (688767.SS), Xiangyu Medical (688626.SS), L&C BIO (290650.KS), Tinavi Medical Technologies (688277.SS).
Is Kuros Biosciences expensive compared with its peers?
On forward p/e it trades at 70.5× against a peer median of 21.7×, 3rd most expensive of 17 in its peer set.
How has Kuros Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -12.5% against -13.2% for the median peer; over one year -29.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.